It is time to accelerate building local vaccine adjuvant manufacturing capacity

Recent accomplishments in vaccine adjuvant development are enabling new vaccines for previously intractable diseases, increased immunity in immunocompromised populations and greater global pandemic preparedness.1,2 To ensure that the potential benefits of vaccine adjuvant technology are widely accessible, it is essential that adjuvant molecules and formulations, as well as the know-how to manufacture and clinically evaluate them, are made available to developing country manufacturers